Amanta Healthcare Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Amanta Healthcare Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹126
Per ShareLot Size
119 Shares
Minimum Investment
₹14,994
Issue Size
₹126 Cr
Face Value
₹10
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Amanta Healthcare Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
85.6%
Promoter Holding (Post-Issue)
63.56%
Issue Type
Book Building
ISIN
INE084K01015
About the Company
We are a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal ("ABFS") and Injection Strech Blow Moulding ("ISBM") technology. We manufacture large volume parenterals ("LVPs") and small volume parenterals ("SVPs") in six therapeutic segments. In addition to that, we also manufacturer medical devices. We manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. We offer wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml. Our formulation and development operations help us to develop new formulation as well as modify improve the formulation for our own brand as well as our customers for product partnering business. We have a dedicated Formulation and Development ("F&D") and quality control laboratory located at our manufacturing facility in Hariyala, District Kheda, Gujarat, India. We have four LVPs manufacturing lines, which include two lines of conventional single port containers with ABFS technology and two lines for SteriPort products with ISBM technology. Similarly, we have three operational SVPs manufacturing lines, which includes two ABFS lines and one conventional three-piece container filling lines. Our manufacturing facility has good manufacturing practices ("GMP") certifications from the Food & Drugs Control Administration, Gujarat, in conformity with the format recommended by the World Health Organization (the "WHO"), the GMP for formulations from Cambodia, Sudan, Philippines, Zimbabwe. We also have certificate from DNV for exports of medical device products. Our cGMP capabilities allow us to offer our customers various products of sterile liquid form in product categories of quinolones, anti-biotics, anti-fungal, diuretic, anti-anaerobic, Ophthalmic, Respiratory etc.
Industry Overview
As per CRISIL Report, as per the International Monetary Fund's (IMF) April 2025 update, global gross domestic product (GDP) growth witnessed a growth of 3.3% in 2024 as signs of stabilization emerged inflation came down from multidecade highs, followed a gradual as well as labor markets normalized, with unemployment and vacancy rates returning to pre pandemic levels, IV fluid market consisting of key products like normal saline, dextrose, lactate ringer and electrolytes have seen traction in recent years owing to growth of overall healthcare system in India. Indian IV fluids market is estimated to be valued at Rs 45-47 billion as of fiscal 2024, compared to ~Rs 29 billion in fiscal 2019. This growth was supported by multiple factors including rising population, increasing prevalence of chronic diseases, and growing demand for IV fluids in medical treatments due to fast acting way. Going ahead with growth of overall healthcare delivery market in India and the factors outlined above the industry is estimated to register a CAGR of 9-11% between fiscals 2024- 2029 and reach Rs. 70-80 billion by fiscal 2029 owning to sustained demand from end use segments like hospitals and clinics. The healthcare budget has seen increases on-year. Between FY11 and FY25, the budget for the MoHFW clocked a CAGR of 10%. In recent years, the utilisation rate has been 100% or above, as has been the case since FY16. This, too, is a strong growth driver for the industry and particularly the PPP initiative from government so as to achieve the government's goal of providing healthcare services to all.
Company History
Our Company was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership firm "Marck Parenterals (India)" under Part IX of the Companies Act, 1956 and received the Certificate for Commencement of Business on January 06, 1995. Subsequently, the name of our Company was changed to "Marck Biosciences Limited" pursuant to a special resolution passed by our shareholders on October 29, 2005. The fresh certificate of incorporation consequent upon change of name was granted on November 05, 2005 by the Registrar of Companies, Gujarat at Ahmedabad. Subsequently, the name of our Company was changed to "Amanta Healthcare Limited" pursuant to a special resolution passed by our shareholders on June 12, 2014, and a fresh certificate of incorporation dated June 24, 2014 issued by the Registrar of Companies Gujarat at Ahmedabad.
Products & Services
- The Company is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container and Injection Strech Blow Moulding ("ISBM") technology.
Growth Strategy
- Expansion of our manufacturing capacities.
- National Sales business.
- Expand National Sales Network.
- Expand the wallet share of existing customers and develop new customers.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of up to 1,00,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of our company for cash at a price of Rs. 126 per equity share (including a Share Premium of Rs. 116 per Equity Share) ("Issue Price") aggregating up to Rs. 126 crores (the "issue") comprising of its post-issue paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Well established manufacturer of pharmaceutical formulations with diverse product portfolio and diverse market.
- Large manufacturing capabilities.
- Wide Domestic and International Marketing Network.
- Experienced management team supported by large, diverse and skilled work force.
- Our Company's entire manufacturing facility is located at a single location, and all of the Company's manufactured products are produced from such facility in village Hariyala, district Kheda, Gujarat. Any delay in production at, or shutdown of, our manufacturing facility due to various factors such as shortage of electrical power or water resources, political instability, industrial accidents or machinery breakdowns, severe weather conditions, natural disasters, and outbreak of infectious diseases may in turn adversely affect our business, financial condition and results of operations.
- Any manufacturing or quality control concerns or our inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by our clients and distributors, which could have an adverse effect on our business, results of operations, financial condition and cash flows.
- Our Company is involved in a certain material litigation and an adverse outcome in this proceeding may adversely affect our business, financial condition and growth strategy.
- We may not be able to improve our profit margins and profits in the future.
- Our Company had issued Equity Shares to more than 49 investors in the past and as a matter of abundant caution for better corporate governance, our Company has given an exit offer to the eligible shareholders.